We observed that high levels of potent androgens and biologically active estrogen metabolites are linked to an improved survival of female CLL patients whereas higher LH levels are associated with shorter survival in male CLL patients. The gene discussed is PLOD1; the disease is B-cell chronic lymphocytic leukemia.